Jazz Pharmaceuticals plc
JAZZ
$138.81
$2.361.73%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 4.07B | 3.99B | 3.91B | 3.84B | 3.83B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.07B | 3.99B | 3.91B | 3.84B | 3.83B |
| Cost of Revenue | 378.98M | 362.95M | 353.49M | 341.13M | 342.77M |
| Gross Profit | 3.69B | 3.63B | 3.56B | 3.50B | 3.49B |
| SG&A Expenses | 1.42B | 1.38B | 1.36B | 1.36B | 1.31B |
| Depreciation & Amortization | 627.31M | 619.96M | 617.39M | 614.23M | 608.28M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.28B | 3.19B | 3.20B | 3.17B | 3.08B |
| Operating Income | 793.37M | 799.35M | 711.53M | 669.73M | 752.09M |
| Income Before Tax | 468.69M | 396.55M | 295.68M | 237.88M | 294.92M |
| Income Tax Expenses | -91.43M | -66.61M | -99.25M | -92.92M | -119.91M |
| Earnings from Continuing Operations | 560.12 | 463.16 | 394.92 | 330.79 | 414.83 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 560.12M | 463.16M | 394.92M | 330.79M | 414.83M |
| EBIT | 793.37M | 799.35M | 711.53M | 669.73M | 752.09M |
| EBITDA | 1.45B | 1.45B | 1.36B | 1.31B | 1.39B |
| EPS Basic | 9.11 | 7.45 | 6.28 | 5.23 | 6.56 |
| Normalized Basic EPS | 5.54 | 5.50 | 4.45 | 3.86 | 4.64 |
| EPS Diluted | 8.79 | 7.10 | 5.82 | 4.85 | 6.12 |
| Normalized Diluted EPS | 5.32 | 5.13 | 4.02 | 3.47 | 4.09 |
| Average Basic Shares Outstanding | 247.37M | 249.41M | 251.11M | 252.22M | 253.18M |
| Average Diluted Shares Outstanding | 256.84M | 265.01M | 273.13M | 277.04M | 288.28M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
